Výsledky vyhledávání - "Alex Kozhich"

Singlicate Ligand Binding Assay Using an Automated Microfluidic System: a Clinical Case Study

Autor: Jonathan Haulenbeek, Kelli R. Phillips, Ross Fergus, Hao Jiang, Craig Titsch, Frank Zambito, Janice Gambardella, Heather Myler, Jennifer Cummings, Alex Kozhich

Publikováno v: The AAPS Journal. 19:1461-1468

The bioanalytical strategy for monoclonal antibody therapeutics, intended for multiple oncology indications, includes multiple integrated measurements of pharmacologically relevant therapeutics from discovery through development. Three ligand binding

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed2be75b7d4c2b7a1cb5766c693d5fcf
https://doi.org/10.1208/s12248-017-0105-5

Zobrazit plný text záznamu

Validation of an integrated series of ligand-binding assays for the quantitative determination of antibody–drug conjugates in biological matrices

Autor: Vangipuram S. Rangan, Amy Manney, Mark Saewert, Ang Liu, Binodh DeSilva, Donna Dail, Jennifer Cummings, Renuka Pillutla, Alex Kozhich, Heather Myler, Chetana Rao, Jian Wang, Brian K. Hoffpauir

Publikováno v: Bioanalysis. 8:519-531

Background: The bioanalytical strategy for antibody–drug conjugates (ADC) includes multiple integrated measurements of pharmacologically relevant ADC. Methods & results: Three ligand-binding assays were validated for the measurement of total antibo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3681fec20a59b885ac063763e7b9d22b
https://doi.org/10.4155/bio.16.13

Zobrazit plný text záznamu

Bioavailability of protein therapeutics in rats following inhalation exposure: Relevance to occupational exposure limit calculations

Autor: Hui Wei, Neil Mathias, Jessica C. Graham, Aaron P. Yamniuk, Bonnie Wang, Irvith M. Carvajal, Julien Susan D, Janet Gould, Helen G. Haggerty, Michael J. Graziano, Jedd Hillegass, Alex Kozhich, Todd Davidson

Publikováno v: Regulatory toxicology and pharmacology : RTP. 100

Protein therapeutics represent a rapidly growing proportion of new medicines being developed by the pharmaceutical industry. As with any new drug, an Occupational Exposure Limit (OEL) should be developed to ensure worker safety. Part of the OEL deter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::864a3503fe07b20b7d2f584e1c2356c3
https://pubmed.ncbi.nlm.nih.gov/30291877

Zobrazit plný text záznamu

Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells

Autor: Christian Brandl, Sandrine d’Argouges, Ralf C. Bargou, Sandra Wissing, Peter Kufer, Alex Kozhich, Mathias Locher, Nadja Prang, Ralf Lutterbuese, Robert Hofmeister, Patrick A. Baeuerle, JoAnn Suzich, Peter A. Kiener

Publikováno v: Leukemia research. 33(3)

We have compared the cytotoxic activity of rituximab with that of blinatumomab (MT103/MEDI-538), a single-chain CD19-/CD3-bispecific antibody engaging human T cells. Blinatumomab consistently led to a higher degree of lysis of human lymphoma lines th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71c8aef7ac7a91290f6d127b9bed8bea
https://pubmed.ncbi.nlm.nih.gov/18835037

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání